RPC1063

Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the… (More)

Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… (More)

Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… (More)

BACKGROUND AND PURPOSE Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac… (More)

BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… (More)

Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… (More)

In its third major acquisition in 3 months, Celgene is buying the biotech company Receptos for US$7.2 billion. In doing so… (More)

antiviral agents, many patients face barriers to access. In our Advances in Hepatology column, Dr David E. Bernstein discusses… (More)

therapy for Crohn’s disease. N Engl J Med 2005; 353:362–368. 6. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction… (More)

Background: RPC1063 is an oral, selective sphingosine 1-phosphate 1 receptor modulator in clinical development for the treatment… (More)